title: Dendritic cell vaccination and immune monitoring.
abstract: We exploited dendritic cells (DC) to vaccinate melanoma patients. We recently demonstrated a statistical significant correlation between favorable clinical outcome and the presence of vaccine-related tumor antigen-specific T cells in delayed type hypersensitivity (DTH) skin biopsies. However, favorable clinical outcome is only observed in a minority of the treated patients. Therefore, it is obvious that current DC-based protocols need to be improved. For this reason, we study in small proof of principle trials the fate, interactions and effectiveness of the injected DC.
authors.affiliation: Department of Medical Oncology, Nijmegen Centre for Molecular Life Sciences, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands.
authors.forename: E H J G
authors.initials: EH
authors.lastname: Aarntzen
authors.forename: C G
authors.initials: CG
authors.lastname: Figdor
authors.forename: G J
authors.initials: GJ
authors.lastname: Adema
authors.forename: C J A
authors.initials: CJ
authors.lastname: Punt
authors.forename: I J M
authors.initials: IJ
authors.lastname: de Vries
mesh_terms: D000818:Animals; D019496:Cancer Vaccines / Q000276:immunology / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D003713:Dendritic Cells / Q000276:immunology*; D006801:Humans; D016219:Immunotherapy, Adoptive / Q000379:methods*; D008545:Melanoma / Q000276:immunology / Q000628:therapy*; D015166:Monitoring, Immunologic / Q000379:methods*; D012878:Skin Neoplasms / Q000276:immunology / Q000628:therapy*
chemical_list: D019496:Cancer Vaccines